GlassScriptPhysician profile
Samuel S Jacobson
NPI 1326020843
$2,807.89
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $261 · 2021: $430 · 2022: $730 · 2023: $693 · 2024: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,014.91 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $839.29 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $532.26 | 2019-2024 | Tezspire, Breztri, Fasenra |
| Grifols USA, LLC | $228.75 | 2019-2023 | Prolastin-C Liquid |
| Electromed, INC. | $143.68 | 2019-2023 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.76 | 2019-2022 | |
| Insmed, INC. | $121.12 | 2022-2024 | Arikayce |
| Olympus America INC. | $114.58 | 2020 | |
| Mylan Specialty L.P. | $95.68 | 2019-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $88.92 | 2022-2024 | Glassia |
| Genentech USA, INC. | $73.20 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $65.56 | 2022-2024 | Acthar |
| Abbvie INC. | $43.92 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $36.84 | 2022 | |
| Philips North America LLC | $31.94 | 2019 | |
| Allergan, INC. | $30.40 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $30.15 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $26.93 | 2022 | |
| Genzyme Corporation | $25.19 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.73 | 2021 | |
| Baxter Healthcare | $23.48 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Paratek Pharmaceuticals, INC. | $22.91 | 2024 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $22.85 | 2024 | Dupixent |
| Vapotherm INC | $16.71 | 2022 | |
| Resmed Corp | $15.47 | 2021 | |
| Gilead Sciences, INC. | $14.67 | 2021 | |
| Zoll Respicardia, INC. | $4.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.